Acro Biomedical (ACBM) Research & Development (2021 - 2023)

Acro Biomedical has reported Research & Development for 3 years, with the latest figure at $396550.0 in Q3 2023.

• On a quarterly basis, Research & Development fell 84.26% year-over-year to $396550.0 in Q3 2023; TTM through Jun 2024 was $396550.0, a 95.8% decrease from a year earlier, with the FY2023 full-year figure at $4.8 million, down 52.43% from the prior year.
• Research & Development was $396550.0 for Q3 2023 at Acro Biomedical, down from $1.9 million in the prior quarter.
• The five-year high for Research & Development was $2.5 million in Q4 2021, with the low at $396550.0 in Q3 2023.
• Average Research & Development over 3 years is $2.0 million, with a median of $2.5 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 292.69% in 2022, then plunged 84.26% in 2023.
• Over 3 years, Research & Development stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then slumped by 84.26% to $396550.0 in 2023.
• The last three Research & Development figures came in at $396550.0 (Q3 2023), $1.9 million (Q2 2023), and $2.5 million (Q1 2023), per Business Quant data.